MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/mr/roab021

Медицинская библиотека · Modern rheumatology · 2022

Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3).

Atsumi Tatsuya, Tanaka Yoshiya, Matsubara Tsukasa, Amano Koichi, Ishiguro Naoki, Sugiyama Eiji, Yamaoka Kunihiro, Westhovens René, Ching Daniel W T, Messina Osvaldo Daniel, Burmester Gerd R, Bartok Beatrix, Pechonkina Alena, Kondo Akira, Yin Zhaoyu, Guo Ying, Tasset Chantal, Sundy John S, Takeuchi Tsutomu

Клиническое исследование III фазыСтатьяРандомизированное исследованиеПеревод в очереди

Аннотация

OBJECTIVES

To evaluate the efficacy and safety of filgotinib for Japanese patients with rheumatoid arthritis (RA) and limited or no prior methotrexate (MTX) exposure.

METHODS

Data up to 24 weeks were analysed for 71 Japanese patients from a 52-week global Phase 3 study. Patients with RA and limited or no prior MTX exposure were randomised in a 2:1:1:2 ratio to filgotinib 200 mg plus MTX, filgotinib 100 mg plus MTX, filgotinib 200 mg, or MTX. Maximum MTX dose was 15 mg/week. Primary endpoint was proportion achieving 20% improvement in American College of Rheumatology criteria (ACR20) at Week 24.

RESULTS

Week 24 ACR20 rates in Japanese patients were 82.6%, 90.9%, 83.3%, and 80.0% for filgotinib 200 mg plus MTX, filgotinib 100 mg plus MTX, filgotinib 200 mg, and MTX, respectively. Greater ACR20 rates with filgotinib vs MTX occurred at Week 2. Greater proportions receiving filgotinib vs MTX achieved DAS28-CRP <2.6 at Weeks 12 and 24. Adverse event rates were comparable across treatments and between the Japanese and overall populations.

CONCLUSIONS

While Week 24 ACR20 rates were similar, filgotinib provided faster responses and higher remission rates vs MTX. In Japanese patients with RA and limited or no prior MTX exposure, filgotinib was generally well tolerated.

Для цитирования: Atsumi Tatsuya, Tanaka Yoshiya, Matsubara Tsukasa, Amano Koichi, Ishiguro Naoki, Sugiyama Eiji, Yamaoka Kunihiro, Westhovens René, Ching Daniel W T, Messina Osvaldo Daniel, Burmester Gerd R, Bartok Beatrix, Pechonkina Alena, Kondo Akira, Yin Zhaoyu, Guo Ying, Tasset Chantal, Sundy John S, Takeuchi Tsutomu. Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3).. Modern rheumatology. 2022. DOI: 10.1093/mr/roab021.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.